The two articles on bupropion in this issue1,2 remind us that this is one of several novel antidepressants that are generally assumed to be effective but are so far not available for the treatment of depressed patients. Bupropion is a particularly frustrating example of this group of drugs that seem always to be just out of reach. It was about to be released to the drug stores two years ago; it was suddenly called back and has not yet become available.
In an editorial a number of years ago, I noted that depression was a very satisfying disorder—good to study,
See also pp 139 and 145.
rewarding to treat, and almost always nicely treatable.3 Over the years, my optimism is wearing thin. One keeps suspecting that the "easy" cases of depression are now being treated by primary care physicians, leaving psychiatrists with a preponderance of depressed patients in